Elizabeta A. Rojas
YOU?
Author Swipe
View article: Exploring the role of cyclin <scp>D1</scp> in the pathogenesis of multiple myeloma beyond cell cycle regulation
Exploring the role of cyclin <span>D1</span> in the pathogenesis of multiple myeloma beyond cell cycle regulation Open
Cyclins D could be a unifying event in multiple myeloma (MM), even though MM is not typically considered a proliferative disease. In this study, we hypothesized that cyclins D might have additional roles in the pathogenesis of MM beyond ce…
View article: HERNIA DIAFRAGMÁTICA SECUNDARIA A EPIPOPLASTIA TRANSDIAFRAGMÁTICA POR FÍSTULA BRONCOPLEURAL
HERNIA DIAFRAGMÁTICA SECUNDARIA A EPIPOPLASTIA TRANSDIAFRAGMÁTICA POR FÍSTULA BRONCOPLEURAL Open
Introduction: Diaphragmatic hernias whose source is different from the non traumatic transhiatal or traumatic (open or closed) are an exceptional pathology, with a scarce bibliography regarding the subject. It is for this matter that we pr…
View article: Human Papillomavirus Genotyping in Colombian Patients with Esophageal Squamous Cell Carcinoma and Gastric Carcinoma
Human Papillomavirus Genotyping in Colombian Patients with Esophageal Squamous Cell Carcinoma and Gastric Carcinoma Open
Introduction: Human papillomavirus (HPV) is one of the most important oncogenic viru-ses detected in different types of cancer, which includes esophageal squamous cell carcino-ma (ESCC) and gastric cancer (GC). However, Colombia does not h…
View article: Expression profile of Bcl‐2 family proteins in newly diagnosed multiple myeloma patients
Expression profile of Bcl‐2 family proteins in newly diagnosed multiple myeloma patients Open
Antiapoptotic Bcl‐2 family proteins are involved in myeloma cell survival. To date, their expression in multiple myeloma (MM) patients has mostly been analyzed at the RNA level. In the present study, we quantified for the first time the pr…
View article: Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling Open
Upregulation of a cyclin D gene determined by expression microarrays is an almost universal event in multiple myeloma (MM), but this finding has not been properly confirmed at the protein level. For this reason, we carried out a quantitati…
View article: P848: EXPRESSION PROFILE OF BCL-2 FAMILY PROTEINS IN MULTIPLE MYELOMA.
P848: EXPRESSION PROFILE OF BCL-2 FAMILY PROTEINS IN MULTIPLE MYELOMA. Open
Topic: 13. Myeloma and other monoclonal gammopathies - Biology & Translational Research Background: Evasion of apoptotic mechanisms due to the deregulation of Bcl-2 family proteins may play an important role in the resistance of multiple m…
View article: SAR442257, a CD38/CD28/CD3 trispecific antibody, potentiates CAR T‐cell activity against large B‐cell lymphoma
SAR442257, a CD38/CD28/CD3 trispecific antibody, potentiates CAR T‐cell activity against large B‐cell lymphoma Open
CART cell therapy has significantly improved outcomes of patients with relapsed/refractory large B cell lymphoma (rrLBCL), but many do not experience long term benefit. The mechanisms of failure are multifaceted including CAR T exhaustion.…
View article: Data from Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma
Data from Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma Open
Purpose: Dysregulation of one of the three D-cyclin genes has been observed in virtually all multiple myeloma tumors. The mechanisms by which CCND2 is upregulated in a set of multiple myeloma are not completely deciphered. We investigated …
View article: Supplementary Figures 1-13 from Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma
Supplementary Figures 1-13 from Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma Open
Figure S1. (A) Protein expression of p53 in MM cell lines.; Figure S2. (A) Melphalan resistant MM cell line RPMI-LR5 (panel left) and dexamethasone resistant MM cell line MM1R (panel right) were treated with the indicated doses of amilorid…
View article: Supplementary data from Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma
Supplementary data from Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma Open
Supplementary Tables Supplementary Table 1. Cytogenetic characteristics of MM samples Supplementary Table 2. Sequences of primers used in the study Supplementary Table 3. CCND2 mRNA FISH probes sequences Supplementary table 4. microRNAs pr…
View article: Data from Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma
Data from Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma Open
Purpose: The search for new drugs that control the continuous relapses of multiple myeloma is still required. Here, we report for the first time the potent antimyeloma activity of amiloride, an old potassium-sparing diuretic approved for t…
View article: Supplementary Data-Data from Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma
Supplementary Data-Data from Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma Open
Supplementary methods, tables and references.
View article: Supplementary Figures 1-13 from Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma
Supplementary Figures 1-13 from Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma Open
Figure S1. (A) Protein expression of p53 in MM cell lines.; Figure S2. (A) Melphalan resistant MM cell line RPMI-LR5 (panel left) and dexamethasone resistant MM cell line MM1R (panel right) were treated with the indicated doses of amilorid…
View article: Data from Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma
Data from Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma Open
Purpose: Dysregulation of one of the three D-cyclin genes has been observed in virtually all multiple myeloma tumors. The mechanisms by which CCND2 is upregulated in a set of multiple myeloma are not completely deciphered. We investigated …
View article: Supplementary data from Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma
Supplementary data from Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma Open
Supplementary Tables Supplementary Table 1. Cytogenetic characteristics of MM samples Supplementary Table 2. Sequences of primers used in the study Supplementary Table 3. CCND2 mRNA FISH probes sequences Supplementary table 4. microRNAs pr…
View article: Supplementary Data-Data from Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma
Supplementary Data-Data from Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma Open
Supplementary methods, tables and references.
View article: Data from Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma
Data from Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma Open
Purpose: The search for new drugs that control the continuous relapses of multiple myeloma is still required. Here, we report for the first time the potent antimyeloma activity of amiloride, an old potassium-sparing diuretic approved for t…
View article: Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling Open
Upregulation of a cyclin D gene determined by expression microarrays is an almost universal event in MM, but this finding has not been properly confirmed at the protein level. For this reason, we carried out a quantitative analysis of cycl…
View article: Transcriptional signature of <i>TP53</i> biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome
Transcriptional signature of <i>TP53</i> biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome Open
Summary Biallelic inactivation of TP53 has been included in the definition of double‐hit (DH) multiple myeloma (MM), which entails an ominous prognosis. However, this condition, or even the presence of high‐risk cytogenetic abnormalities, …
View article: P846: EXPRESSION SIGNATURE OF TP53 BIALLELIC INACTIVATION IDENTIFIES A GROUP OF MULTIPLE MYELOMA PATIENTS WITHOUT THIS GENETIC CONDITION BUT WITH DISMAL OUTCOME.
P846: EXPRESSION SIGNATURE OF TP53 BIALLELIC INACTIVATION IDENTIFIES A GROUP OF MULTIPLE MYELOMA PATIENTS WITHOUT THIS GENETIC CONDITION BUT WITH DISMAL OUTCOME. Open
Background: Cytogenetic abnormalities remain the most relevant prognostic factors, especially those related to TP53 gene. Biallelic inactivation of TP53, included in the definition of double-hit (DH) MM, entails an ominous prognosis, altho…
View article: Genomics of Plasma Cell Leukemia
Genomics of Plasma Cell Leukemia Open
Plasma cell leukemia (PCL) is a rare and highly aggressive plasma cell dyscrasia characterized by the presence of clonal circulating plasma cells in peripheral blood. PCL accounts for approximately 2–4% of all multiple myeloma (MM) cases. …
View article: Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome.
Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome. Open
Background : Biallelic inactivation of TP53 has been included in the definition of double-hit (DH) multiple myeloma (MM), which entails an ominous prognosis even when treated with the most innovative drugs. However, this condition, or even…
View article: Expression of p53 protein isoforms predicts survival in patients with multiple myeloma
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma Open
Loss and/or mutation of the TP53 gene are associated with short survival in multiple myeloma, but the p53 landscape goes far beyond. At least 12 p53 protein isoforms have been identified as a result of a combination of alternative splicing…
View article: Additional file 3 of RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation
Additional file 3 of RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation Open
Additional file 3: Table S2. List of differential usage of exons from RNA-seq.
View article: Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma
Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma Open
The search for biomarkers based on the mechanism of drug action has not been thoroughly addressed in the therapeutic approaches to multiple myeloma (MM), mainly because of the difficulty in analyzing proteins obtained from purified plasma …
View article: Effect of Graphene Family Materials on Multiple Myeloma and Non-Hodgkin’s Lymphoma Cell Lines
Effect of Graphene Family Materials on Multiple Myeloma and Non-Hodgkin’s Lymphoma Cell Lines Open
The interest around the graphene family of materials is constantly growing due to their potential application in biomedical fields. The effect of graphene and its derivatives on cells varies amongst studies depending on the cell and tissue…